interleukin-17


Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to interleukin-17: IL-17F

in·ter·leu·kin-17

(in'tĕr-lū'kin),
A proinflammatory cytokine made by T cells.

in·ter·leu·kin-17

(in'tĕr-lū'kin)
A proinflammatory cytokine made by T cells.

interleukin-17

Abbreviation: IL-17
A cytokine produced by memory T lymphocytes that stimulates the proliferation of T cells and the differentiation of neutrophils.
See also: interleukin

interleukin-17

,

IL-17

A cytokine produced by memory T lymphocytes that stimulates the proliferation of T cells and the differentiation of neutrophils.
References in periodicals archive ?
005) (A), and between interleukin-17 (IL-17) and interleukin-23 (IL-23, P=0.
Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2dependent NF-kappaB and C/EBPbeta activation.
Serum interleukin-17 levels are related to clinical severity in allergic rhinitis.
Expression of interleukin-17 in hepatitis B related liver fibrosis].
3] Nonstandard abbreviations: Th1, T helper 1 (cells); mAb, monoclonal antibody; apo B, apolipoprotein B; IL-17, interleukin-17.
Interleukin-17 may have a central role in inflammatory joint diseases as a "fine-tuning" cytokine.
Interleukin-17 is a proinflammatory cytokine with very pleiotropic biological functions.
Ensemble's internal discovery and development efforts are focused on the key therapeutic areas of oncology and immuno-inflammatory diseases, with its lead program, a small molecule antagonist of Interleukin-17, a cytokine implicated in multiple inflammatory and autoimmune diseases, poised to enter development with an orally active candidate in 2013.
Moreover, global mRNA expression for key genes involved in the interleukin-23 / interleukin-17 inflammatory cytokine pathway closely resembled healthy skin following treatment with secukinumab.
According to the company, SILIQ is a novel human monoclonal antibody that binds to the interleukin-17 (IL-17) receptor and inhibits inflammatory signaling by preventing the binding of several types of IL-17 to the receptor.
This growth will be driven primarily by the highly anticipated arrivals of promising systemic therapies- interleukin-23 (IL-23) inhibitors (guselkumab and tildrakizumab), interleukin-17 (IL-17) inhibitors (Cosentyx, Taltz, and brodalumab) as well as phsophodiesterase (PDE4) inhibitor- Otezla (apremilast).
Rheumatoid arthritis is a chronic disease driven by multiple cytokines, including TNF-alpha, interleukin-6, and interleukin-17, produced by pro-inflammatory monocytes/macrophages and activated T cells.